DNA Methyltransferase-1 (DNMT1): A Flow Cytometric Pharmacodynamic Assay for Azacitidine Hypomethylating Therapy after Allogeneic Hematopoietic Stem Cell Transplantation (AlloSCT)
Loading...
Date
2015
Journal Title
Journal ISSN
Volume Title
Type
Article
Publisher
ELSEVIER
Series Info
Biology of Blood and Marrow Transplantation;VOL : 21 Issue : 2
Scientific Journal Rankings
Abstract
Disease relapse is a major cause of treatment failure following alloSCT for acute myeloid leukemia (AML). Azacitidine has shown efficacy in treating, and preventing, post-transplant relapse in patients with AML. Post-SCT azacitidine administration is challenging due to the possibility of myelosuppression and an incomplete understanding of the optimal dose and schedule. DNMT1 is responsible for genome methylation in S phase and degraded after bonding irreversibly to substituted DNA. Hence, the DNMT1 level may be an attractive pharmacodynamic (PD) endpoint for azacitidine therapy
Description
MSA Google Scholar
Keywords
DNA Methyltransferase-1 (DNMT1), DNA, Cytometric, Pharmacodynamic, Azacitidine, Hypomethylating, Allogeneic Hematopoietic Stem Cell Transplantation (AlloSCT)